RNDr. Tomáš Etrych, PhD., DSc.
Curriculum vitae
Education
|
1997 |
M.S. degree in physical chemistry, Charles University, Prague, Czech Republic |
|
2002 |
PhD. degree in macromolecular chemistry, Inst. Macromol. Chem., CAS and Charles University, Prague, Czech Republic |
|
2017 |
DSc. degree in macromolecular chemistry, Academy of Sciences |
Employment
|
2002–2008 |
Research fellow, IMC CAS |
|
from 2008 |
Senior research fellow, IMC CAS |
|
from 2015 |
Head of the Centre of Biomacromolecular and Bioanalogous Systems and head of dept. Biomedical polymers, IMC CAS |
|
2015–2020 |
Head of Laboratory of polymer therapeutics and diagnostics, BIOCEV center, Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University, in Vestec |
|
from 2020 |
Head of the research program „Biomaterials and Tissue Engineering“ of the BIOCEV center |
Research fellowships
|
1996 |
University of Athens, Greece (5 months) |
|
2002–2003 |
University of Montpellier, France (13 months) |
Awards
|
2002 |
Winner of the prize „Prix de Pharmacie 2002“ organized by French Embassy in the Czech Republic |
|
2002 |
Post-doc fellowship awarded by French Ministry of Youth, Education and Research |
|
2006 |
Hlavka’s price for young students and scientists |
|
2008 |
Otto Wichterle’s Award organized by CAS |
Memberships
- Member of Academic assembly of CAS
- Member of the Council for Foreign Relations of CAS
- Member of the Board of IMC CAS
- Member of the editorial board of the Journal of Controlled Release
- Member of the editorial board of the Pharmaceutics
- Member of the evaluation panel 207 of the Grant Agency of the Czech Republic
Mentoring experience
- Advisor of 8 PhD students, 3 master students and 10 bachelor students.
Research project
During the past 10 years, PI or co-PI of 12 research projects financed by national resources (GA CR, GA AV, AZV), main coordinator of project BIOPOL financed by the Ministry of Education, Youth and Sport by OP Education for competitiveness, co-coordinator of project BIOCEV-FAR financed from National susceptibility program II.
